nodes	percent_of_prediction	percent_of_DWPC	metapath
Perhexiline—CYP3A4—bone cancer	0.845	1	CbGaD
Perhexiline—CYP2B6—Cisplatin—bone cancer	0.0475	0.455	CbGbCtD
Perhexiline—CYP2B6—Doxorubicin—bone cancer	0.0318	0.305	CbGbCtD
Perhexiline—CYP2D6—Doxorubicin—bone cancer	0.0154	0.147	CbGbCtD
Perhexiline—CYP3A4—Doxorubicin—bone cancer	0.00977	0.0936	CbGbCtD
Perhexiline—Papilloedema—Cisplatin—bone cancer	0.00304	0.0825	CcSEcCtD
Perhexiline—Cachexia—Epirubicin—bone cancer	0.00174	0.0471	CcSEcCtD
Perhexiline—Cachexia—Doxorubicin—bone cancer	0.00161	0.0436	CcSEcCtD
Perhexiline—Optic neuritis—Cisplatin—bone cancer	0.00157	0.0427	CcSEcCtD
Perhexiline—Polyneuropathy—Epirubicin—bone cancer	0.00152	0.0413	CcSEcCtD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—FEV—bone cancer	0.00147	0.105	CbGpPWpGaD
Perhexiline—Polyneuropathy—Doxorubicin—bone cancer	0.00141	0.0383	CcSEcCtD
Perhexiline—Liver injury—Cisplatin—bone cancer	0.00115	0.0312	CcSEcCtD
Perhexiline—CPT2—PPAR Alpha Pathway—CDK4—bone cancer	0.00109	0.0776	CbGpPWpGaD
Perhexiline—Hepatocellular injury—Cisplatin—bone cancer	0.000966	0.0262	CcSEcCtD
Perhexiline—Optic neuritis—Epirubicin—bone cancer	0.000806	0.0219	CcSEcCtD
Perhexiline—CPT1A—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000771	0.0551	CbGpPWpGaD
Perhexiline—CPT1A—PPAR Alpha Pathway—CDK4—bone cancer	0.000754	0.0538	CbGpPWpGaD
Perhexiline—Optic neuritis—Doxorubicin—bone cancer	0.000746	0.0203	CcSEcCtD
Perhexiline—CYP2B6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000735	0.0525	CbGpPWpGaD
Perhexiline—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.000618	0.0441	CbGpPWpGaD
Perhexiline—Liver injury—Epirubicin—bone cancer	0.000589	0.016	CcSEcCtD
Perhexiline—Liver injury—Doxorubicin—bone cancer	0.000545	0.0148	CcSEcCtD
Perhexiline—Neuropathy peripheral—Cisplatin—bone cancer	0.00053	0.0144	CcSEcCtD
Perhexiline—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000513	0.0366	CbGpPWpGaD
Perhexiline—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000511	0.0365	CbGpPWpGaD
Perhexiline—Gait disturbance—Epirubicin—bone cancer	0.000508	0.0138	CcSEcCtD
Perhexiline—Hepatocellular injury—Epirubicin—bone cancer	0.000496	0.0135	CcSEcCtD
Perhexiline—Gait disturbance—Doxorubicin—bone cancer	0.00047	0.0128	CcSEcCtD
Perhexiline—Hepatocellular injury—Doxorubicin—bone cancer	0.000459	0.0125	CcSEcCtD
Perhexiline—Flushing—Cisplatin—bone cancer	0.00045	0.0122	CcSEcCtD
Perhexiline—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000397	0.0284	CbGpPWpGaD
Perhexiline—Tremor—Cisplatin—bone cancer	0.000396	0.0107	CcSEcCtD
Perhexiline—Hypoglycaemia—Epirubicin—bone cancer	0.000369	0.01	CcSEcCtD
Perhexiline—Convulsion—Cisplatin—bone cancer	0.000366	0.00994	CcSEcCtD
Perhexiline—Ataxia—Methotrexate—bone cancer	0.000362	0.00983	CcSEcCtD
Perhexiline—Diplopia—Epirubicin—bone cancer	0.00036	0.00978	CcSEcCtD
Perhexiline—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.000355	0.0253	CbGpPWpGaD
Perhexiline—Hypoglycaemia—Doxorubicin—bone cancer	0.000341	0.00927	CcSEcCtD
Perhexiline—Ataxia—Epirubicin—bone cancer	0.000339	0.0092	CcSEcCtD
Perhexiline—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000334	0.0238	CbGpPWpGaD
Perhexiline—Diplopia—Doxorubicin—bone cancer	0.000333	0.00905	CcSEcCtD
Perhexiline—Hyperhidrosis—Cisplatin—bone cancer	0.000333	0.00905	CcSEcCtD
Perhexiline—Anorexia—Cisplatin—bone cancer	0.000328	0.00892	CcSEcCtD
Perhexiline—Muscular weakness—Epirubicin—bone cancer	0.000318	0.00863	CcSEcCtD
Perhexiline—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.000316	0.0226	CbGpPWpGaD
Perhexiline—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000314	0.0224	CbGpPWpGaD
Perhexiline—Ataxia—Doxorubicin—bone cancer	0.000313	0.00851	CcSEcCtD
Perhexiline—Paraesthesia—Cisplatin—bone cancer	0.000309	0.00841	CcSEcCtD
Perhexiline—Decreased appetite—Cisplatin—bone cancer	0.0003	0.00814	CcSEcCtD
Perhexiline—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000295	0.021	CbGpPWpGaD
Perhexiline—Muscular weakness—Doxorubicin—bone cancer	0.000294	0.00798	CcSEcCtD
Perhexiline—Sweating—Methotrexate—bone cancer	0.000284	0.00772	CcSEcCtD
Perhexiline—Weight decreased—Epirubicin—bone cancer	0.000282	0.00765	CcSEcCtD
Perhexiline—Neuropathy peripheral—Epirubicin—bone cancer	0.000272	0.00739	CcSEcCtD
Perhexiline—Hepatitis—Methotrexate—bone cancer	0.000266	0.00723	CcSEcCtD
Perhexiline—Sweating—Epirubicin—bone cancer	0.000266	0.00723	CcSEcCtD
Perhexiline—CPT1A—Circadian rythm related genes—GNA11—bone cancer	0.000261	0.0186	CbGpPWpGaD
Perhexiline—Weight decreased—Doxorubicin—bone cancer	0.00026	0.00708	CcSEcCtD
Perhexiline—CPT1A—Circadian rythm related genes—EZH2—bone cancer	0.00026	0.0186	CbGpPWpGaD
Perhexiline—Neuropathy peripheral—Doxorubicin—bone cancer	0.000252	0.00684	CcSEcCtD
Perhexiline—Hepatitis—Epirubicin—bone cancer	0.000249	0.00677	CcSEcCtD
Perhexiline—Asthenia—Cisplatin—bone cancer	0.000247	0.00672	CcSEcCtD
Perhexiline—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000247	0.0176	CbGpPWpGaD
Perhexiline—Sweating—Doxorubicin—bone cancer	0.000246	0.00669	CcSEcCtD
Perhexiline—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000244	0.0174	CbGpPWpGaD
Perhexiline—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000237	0.0169	CbGpPWpGaD
Perhexiline—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000232	0.0166	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—NDUFA12—bone cancer	0.000232	0.0166	CbGpPWpGaD
Perhexiline—Flushing—Epirubicin—bone cancer	0.000231	0.00628	CcSEcCtD
Perhexiline—Hepatitis—Doxorubicin—bone cancer	0.00023	0.00626	CcSEcCtD
Perhexiline—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00022	0.0157	CbGpPWpGaD
Perhexiline—Vomiting—Cisplatin—bone cancer	0.000219	0.00595	CcSEcCtD
Perhexiline—Rash—Cisplatin—bone cancer	0.000217	0.0059	CcSEcCtD
Perhexiline—Dermatitis—Cisplatin—bone cancer	0.000217	0.0059	CcSEcCtD
Perhexiline—Flushing—Doxorubicin—bone cancer	0.000214	0.00581	CcSEcCtD
Perhexiline—Tension—Epirubicin—bone cancer	0.000213	0.00578	CcSEcCtD
Perhexiline—Nervousness—Epirubicin—bone cancer	0.000211	0.00572	CcSEcCtD
Perhexiline—Nausea—Cisplatin—bone cancer	0.000205	0.00556	CcSEcCtD
Perhexiline—Convulsion—Methotrexate—bone cancer	0.000201	0.00545	CcSEcCtD
Perhexiline—Tension—Doxorubicin—bone cancer	0.000197	0.00535	CcSEcCtD
Perhexiline—Nervousness—Doxorubicin—bone cancer	0.000195	0.00529	CcSEcCtD
Perhexiline—Syncope—Epirubicin—bone cancer	0.000194	0.00528	CcSEcCtD
Perhexiline—CPT2—Metabolism—NT5C3A—bone cancer	0.000192	0.0137	CbGpPWpGaD
Perhexiline—Loss of consciousness—Epirubicin—bone cancer	0.000191	0.00518	CcSEcCtD
Perhexiline—Convulsion—Epirubicin—bone cancer	0.000188	0.0051	CcSEcCtD
Perhexiline—Hyperhidrosis—Methotrexate—bone cancer	0.000183	0.00497	CcSEcCtD
Perhexiline—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000181	0.0129	CbGpPWpGaD
Perhexiline—Anorexia—Methotrexate—bone cancer	0.00018	0.0049	CcSEcCtD
Perhexiline—Syncope—Doxorubicin—bone cancer	0.00018	0.00489	CcSEcCtD
Perhexiline—Loss of consciousness—Doxorubicin—bone cancer	0.000176	0.00479	CcSEcCtD
Perhexiline—Shock—Epirubicin—bone cancer	0.000174	0.00473	CcSEcCtD
Perhexiline—Convulsion—Doxorubicin—bone cancer	0.000174	0.00472	CcSEcCtD
Perhexiline—Hyperhidrosis—Epirubicin—bone cancer	0.000171	0.00465	CcSEcCtD
Perhexiline—Insomnia—Methotrexate—bone cancer	0.000171	0.00465	CcSEcCtD
Perhexiline—Paraesthesia—Methotrexate—bone cancer	0.00017	0.00461	CcSEcCtD
Perhexiline—Anorexia—Epirubicin—bone cancer	0.000169	0.00458	CcSEcCtD
Perhexiline—Decreased appetite—Methotrexate—bone cancer	0.000164	0.00447	CcSEcCtD
Perhexiline—Fatigue—Methotrexate—bone cancer	0.000163	0.00443	CcSEcCtD
Perhexiline—Shock—Doxorubicin—bone cancer	0.000161	0.00438	CcSEcCtD
Perhexiline—CPT1A—Metabolism—NDUFA12—bone cancer	0.000161	0.0115	CbGpPWpGaD
Perhexiline—Insomnia—Epirubicin—bone cancer	0.00016	0.00435	CcSEcCtD
Perhexiline—Paraesthesia—Epirubicin—bone cancer	0.000159	0.00432	CcSEcCtD
Perhexiline—Hyperhidrosis—Doxorubicin—bone cancer	0.000158	0.0043	CcSEcCtD
Perhexiline—Anorexia—Doxorubicin—bone cancer	0.000156	0.00424	CcSEcCtD
Perhexiline—Gastrointestinal pain—Methotrexate—bone cancer	0.000155	0.0042	CcSEcCtD
Perhexiline—Decreased appetite—Epirubicin—bone cancer	0.000154	0.00418	CcSEcCtD
Perhexiline—Fatigue—Epirubicin—bone cancer	0.000153	0.00414	CcSEcCtD
Perhexiline—Urticaria—Methotrexate—bone cancer	0.00015	0.00408	CcSEcCtD
Perhexiline—Abdominal pain—Methotrexate—bone cancer	0.000149	0.00406	CcSEcCtD
Perhexiline—Insomnia—Doxorubicin—bone cancer	0.000148	0.00402	CcSEcCtD
Perhexiline—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000147	0.0105	CbGpPWpGaD
Perhexiline—Paraesthesia—Doxorubicin—bone cancer	0.000147	0.00399	CcSEcCtD
Perhexiline—CPT1A—AMPK Signaling—TP53—bone cancer	0.000147	0.0105	CbGpPWpGaD
Perhexiline—CPT1A—Circadian rythm related genes—CDK4—bone cancer	0.000147	0.0105	CbGpPWpGaD
Perhexiline—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000145	0.0104	CbGpPWpGaD
Perhexiline—Gastrointestinal pain—Epirubicin—bone cancer	0.000145	0.00393	CcSEcCtD
Perhexiline—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000144	0.0103	CbGpPWpGaD
Perhexiline—Decreased appetite—Doxorubicin—bone cancer	0.000142	0.00387	CcSEcCtD
Perhexiline—Fatigue—Doxorubicin—bone cancer	0.000141	0.00383	CcSEcCtD
Perhexiline—Urticaria—Epirubicin—bone cancer	0.000141	0.00382	CcSEcCtD
Perhexiline—Abdominal pain—Epirubicin—bone cancer	0.00014	0.0038	CcSEcCtD
Perhexiline—Asthenia—Methotrexate—bone cancer	0.000136	0.00369	CcSEcCtD
Perhexiline—Gastrointestinal pain—Doxorubicin—bone cancer	0.000134	0.00364	CcSEcCtD
Perhexiline—CPT1A—Metabolism—NT5C3A—bone cancer	0.000133	0.00951	CbGpPWpGaD
Perhexiline—Urticaria—Doxorubicin—bone cancer	0.00013	0.00353	CcSEcCtD
Perhexiline—Abdominal pain—Doxorubicin—bone cancer	0.000129	0.00352	CcSEcCtD
Perhexiline—Asthenia—Epirubicin—bone cancer	0.000127	0.00345	CcSEcCtD
Perhexiline—Dizziness—Methotrexate—bone cancer	0.000125	0.0034	CcSEcCtD
Perhexiline—Vomiting—Methotrexate—bone cancer	0.00012	0.00327	CcSEcCtD
Perhexiline—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000119	0.00853	CbGpPWpGaD
Perhexiline—Rash—Methotrexate—bone cancer	0.000119	0.00324	CcSEcCtD
Perhexiline—Dermatitis—Methotrexate—bone cancer	0.000119	0.00324	CcSEcCtD
Perhexiline—Headache—Methotrexate—bone cancer	0.000118	0.00322	CcSEcCtD
Perhexiline—Asthenia—Doxorubicin—bone cancer	0.000117	0.00319	CcSEcCtD
Perhexiline—Dizziness—Epirubicin—bone cancer	0.000117	0.00318	CcSEcCtD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000116	0.00827	CbGpPWpGaD
Perhexiline—Vomiting—Epirubicin—bone cancer	0.000113	0.00306	CcSEcCtD
Perhexiline—Nausea—Methotrexate—bone cancer	0.000112	0.00305	CcSEcCtD
Perhexiline—Rash—Epirubicin—bone cancer	0.000112	0.00303	CcSEcCtD
Perhexiline—Dermatitis—Epirubicin—bone cancer	0.000111	0.00303	CcSEcCtD
Perhexiline—Headache—Epirubicin—bone cancer	0.000111	0.00301	CcSEcCtD
Perhexiline—Dizziness—Doxorubicin—bone cancer	0.000108	0.00294	CcSEcCtD
Perhexiline—Nausea—Epirubicin—bone cancer	0.000105	0.00286	CcSEcCtD
Perhexiline—Vomiting—Doxorubicin—bone cancer	0.000104	0.00283	CcSEcCtD
Perhexiline—Rash—Doxorubicin—bone cancer	0.000103	0.0028	CcSEcCtD
Perhexiline—Dermatitis—Doxorubicin—bone cancer	0.000103	0.0028	CcSEcCtD
Perhexiline—Headache—Doxorubicin—bone cancer	0.000103	0.00279	CcSEcCtD
Perhexiline—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000102	0.00731	CbGpPWpGaD
Perhexiline—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000101	0.00721	CbGpPWpGaD
Perhexiline—Nausea—Doxorubicin—bone cancer	9.73e-05	0.00264	CcSEcCtD
Perhexiline—CPT1A—Circadian rythm related genes—JUN—bone cancer	9.46e-05	0.00675	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—ENO2—bone cancer	8.42e-05	0.00601	CbGpPWpGaD
Perhexiline—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.3e-05	0.00593	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—DHFR—bone cancer	7.81e-05	0.00557	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—GNA11—bone cancer	7.3e-05	0.00521	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—CYP3A4—bone cancer	6.62e-05	0.00472	CbGpPWpGaD
Perhexiline—CPT2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.58e-05	0.0047	CbGpPWpGaD
Perhexiline—CYP2B6—Biological oxidations—CYP3A4—bone cancer	6.34e-05	0.00453	CbGpPWpGaD
Perhexiline—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	6.26e-05	0.00447	CbGpPWpGaD
Perhexiline—CPT1A—Circadian rythm related genes—TP53—bone cancer	6.24e-05	0.00446	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—ENO2—bone cancer	5.83e-05	0.00416	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—GSTP1—bone cancer	5.66e-05	0.00404	CbGpPWpGaD
Perhexiline—CYP2B6—Biological oxidations—GSTP1—bone cancer	5.43e-05	0.00387	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—DHFR—bone cancer	5.41e-05	0.00386	CbGpPWpGaD
Perhexiline—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	5.35e-05	0.00382	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—GNA11—bone cancer	5.06e-05	0.00361	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—CYP3A4—bone cancer	4.59e-05	0.00327	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.56e-05	0.00326	CbGpPWpGaD
Perhexiline—CYP2D6—Biological oxidations—CYP3A4—bone cancer	4.41e-05	0.00315	CbGpPWpGaD
Perhexiline—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	4.35e-05	0.0031	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—GSTP1—bone cancer	3.92e-05	0.0028	CbGpPWpGaD
Perhexiline—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.81e-05	0.00272	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—NDUFA12—bone cancer	3.8e-05	0.00271	CbGpPWpGaD
Perhexiline—CYP2D6—Biological oxidations—GSTP1—bone cancer	3.77e-05	0.00269	CbGpPWpGaD
Perhexiline—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	3.72e-05	0.00266	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—NT5C3A—bone cancer	3.15e-05	0.00225	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—PTGS2—bone cancer	2.93e-05	0.00209	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—NDUFA12—bone cancer	2.64e-05	0.00189	CbGpPWpGaD
Perhexiline—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.47e-05	0.00176	CbGpPWpGaD
Perhexiline—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.43e-05	0.00174	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—NT5C3A—bone cancer	2.19e-05	0.00156	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—PTGS2—bone cancer	2.03e-05	0.00145	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—NDUFA12—bone cancer	1.73e-05	0.00123	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—NT5C3A—bone cancer	1.43e-05	0.00102	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—ENO2—bone cancer	1.38e-05	0.000985	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—DHFR—bone cancer	1.28e-05	0.000914	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—GNA11—bone cancer	1.2e-05	0.000854	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—CYP3A4—bone cancer	1.09e-05	0.000775	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—ENO2—bone cancer	9.59e-06	0.000685	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—GSTP1—bone cancer	9.28e-06	0.000662	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—DHFR—bone cancer	8.9e-06	0.000635	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—GNA11—bone cancer	8.32e-06	0.000594	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—CYP3A4—bone cancer	7.54e-06	0.000538	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—GSTP1—bone cancer	6.45e-06	0.00046	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—ENO2—bone cancer	6.27e-06	0.000448	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—DHFR—bone cancer	5.82e-06	0.000415	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—GNA11—bone cancer	5.44e-06	0.000388	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—PTGS2—bone cancer	4.81e-06	0.000343	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—GSTP1—bone cancer	4.22e-06	0.000301	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—PTGS2—bone cancer	3.34e-06	0.000239	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—PTGS2—bone cancer	2.18e-06	0.000156	CbGpPWpGaD
